- Home
- DDL vs MLYS Comparison
DDL vs MLYS Comparison
Compare DDL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDL
- MLYS
- Stock Information
- Founded
- DDL 2014
- MLYS 2019
- Country
- DDL China
- MLYS United States
- Employees
- DDL N/A
- MLYS N/A
- Industry
- DDL Catalog/Specialty Distribution
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- DDL Consumer Discretionary
- MLYS Health Care
- Exchange
- DDL Nasdaq
- MLYS Nasdaq
- Market Cap
- DDL 745.0M
- MLYS 609.7M
- IPO Year
- DDL 2021
- MLYS 2023
- Fundamental
- Price
- DDL $4.07
- MLYS $12.34
- Analyst Decision
- DDL Sell
- MLYS Strong Buy
- Analyst Count
- DDL 1
- MLYS 2
- Target Price
- DDL $1.15
- MLYS $30.00
- AVG Volume (30 Days)
- DDL 1.1M
- MLYS 163.5K
- Earning Date
- DDL 11-06-2024
- MLYS 11-11-2024
- Dividend Yield
- DDL N/A
- MLYS N/A
- EPS Growth
- DDL N/A
- MLYS N/A
- EPS
- DDL 0.13
- MLYS N/A
- Revenue
- DDL $3,158,412,712.00
- MLYS N/A
- Revenue This Year
- DDL $11.04
- MLYS N/A
- Revenue Next Year
- DDL $10.96
- MLYS N/A
- P/E Ratio
- DDL $31.25
- MLYS N/A
- Revenue Growth
- DDL 4.61
- MLYS N/A
- 52 Week Low
- DDL $1.07
- MLYS $7.37
- 52 Week High
- DDL $4.79
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- DDL 49.51
- MLYS 47.76
- Support Level
- DDL $3.88
- MLYS $11.19
- Resistance Level
- DDL $4.24
- MLYS $12.57
- Average True Range (ATR)
- DDL 0.25
- MLYS 0.80
- MACD
- DDL -0.05
- MLYS -0.06
- Stochastic Oscillator
- DDL 20.88
- MLYS 43.07
About DDL Dingdong (Cayman) Limited (each two representing three)
Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.